ResearchPod Summary
Circulating tumor DNA (ctDNA) is increasingly used to identify molecular residual disease (MRD)—the presence of cancer cells detectable at the molecular level even when traditional radiographic imaging shows no signs of disease. Because ctDNA testing is highly prognostic, it has the potential to redefine how clinicians stratify patients after surgery. Studies, such as the Japanese GALAXY study, have demonstrated that patients who test positive for ctDNA post-surgery face a significantly higher risk of recurrence compared to those who test negative, independent of traditional staging criteria.
The appeal of ctDNA testing lies in its ability to personalize adjuvant treatment. By identifying who is truly at high risk, clinicians hope to escalate treatment for those with detectable disease while de-escalating (or omitting) chemotherapy for those who are ctDNA-negative, thereby sparing them from unnecessary toxicity.
However, clinical trial results have been mixed. In the DYNAMIC-II trial, ctDNA-guided management successfully reduced chemotherapy use for stage II colon cancer without compromising recurrence-free survival. Conversely, the DYNAMIC-III trial, which applied similar strategies to patients with stage III colon cancer, failed to prove the noninferiority of a ctDNA-guided approach. In that study, patients whose treatment was de-escalated based on ctDNA status did not fare as well as those receiving standard care, and intensifying chemotherapy for those who were ctDNA-positive did not improve survival outcomes.
Because simply intensifying existing chemotherapy regimens has not yet proven successful for MRD, researchers are pivoting toward novel, MRD-specific treatment strategies. These include immunotherapies, cellular therapies, and antibody-drug conjugates. Furthermore, the FDA is evaluating how ctDNA can be used as a biomarker in clinical trials, though it is not yet recognized as a surrogate endpoint for long-term clinical benefit. The ongoing challenge remains to determine whether acting on detectable ctDNA—before it manifests as visible, macroscopic tumor growth—can actually prevent recurrence and save lives.
Alex: Finding cancer left after surgery does not automatically tell us how to treat it. Blood tests can identify patients likely to relapse, but using those results to change chemotherapy has produced mixed results.
Sam: That sounds like a gap between detecting a problem and knowing what to do. What kind of evidence are we looking at?
Alex: This is a news review by Meg Barbor, reporting on Scott Kopetz’s conference presentation. He’s a colorectal cancer specialist at MD Anderson. The report brings together observational studies, randomized trials, and treatments still being investigated.
Sam: So it matters both to people trying to spare patients chemotherapy and to researchers developing treatments for cancer that scans cannot see.
Alex: Yes. The stakes are unnecessary treatment on one side, and preventable recurrence on the other. We’ll separate prediction from treatment benefit, compare the trials, and ask what a disappearing blood signal actually proves.
Sam: Start with the blood signal. What is being detected when imaging says there is no cancer?
Alex: Circulating tumor DNA means tumor-derived DNA found in the blood. After treatment intended to cure colorectal cancer, detecting it can identify molecular residual disease: cancer remaining at a molecularly detectable level, despite clear scans.
Sam: The report quotes Kopetz objecting to calling that just a high-risk marker. Why does that distinction matter?
Alex: He describes it as molecular persistence of disease, rather than merely a warning about future risk. But that distinction does not settle the treatment question. Evidence that disease remains is not evidence that a particular intervention will eliminate it.
Sam: How convincing is the evidence that a positive result really separates patients with different outcomes?
Alex: The Japanese GALAXY study evaluated about twenty-one hundred patients during the postoperative testing window. Those testing positive had much poorer disease-free survival than those testing negative. That association remained strong after accounting for conventional risk factors, including disease stage and molecular characteristics.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.
Sam: Could that still just be another way of recognizing advanced disease? Otherwise, I would expect stage to remain the dominant divider.
Alex: The INTERCEPT study provides a striking comparison. Patients whose stage four colorectal cancer had been surgically removed, and who tested negative, did better than patients with stage two disease who tested positive. That shows how strongly the blood result can distinguish prognosis across stages.
Sam: Prognosis is one thing. If doctors already treated positive patients more aggressively, could observational results tell us whether that treatment helped?
Alex: Not reliably. In GALAXY, postoperative chemotherapy was associated with better outcomes among positive patients, but no significant benefit was observed among negative patients. Because treatment was not randomized, that cannot establish whether the blood result predicts chemotherapy benefit.
Sam: So the new step is not simply finding a stronger association. It is assigning treatment strategies and testing whether acting on the result works.
Alex: That is where the randomized trials come in. The approach uses the blood result to reduce chemotherapy for some patients, or intensify it for others. Here, adjuvant chemotherapy means chemotherapy after surgery, intended to reduce recurrence risk.
Sam: Which trial gives the clearest example of using the test to spare treatment?
Alex: DYNAMIC-II studied stage two colon cancer. Chemotherapy use was twenty-eight percent with standard management. With blood-test-guided management, it was fifteen percent. The guided strategy therefore treated fewer patients, while meeting the trial’s prespecified noninferiority criteria for recurrence-free survival.
Sam: Noninferiority can sound like the treatments were identical. What does it mean for this comparison?
Alex: It means the guided strategy met the trial’s rule for not being worse beyond a prespecified acceptable margin. At two years, recurrence-free survival was similar between groups. It supports that particular strategy in stage two colon cancer, not unrestricted chemotherapy reduction.
Sam: That scope matters. If the same strategy failed in a different stage, the general message would change considerably.
Alex: And that is what makes DYNAMIC-III essential reading alongside it. This trial studied stage three colon cancer. It reduced treatment intensity for patients testing negative and increased intensity for those testing positive.
Sam: Let’s take the negative group first. Did reducing chemotherapy preserve outcomes there too?
Alex: Among seven hundred and two negative patients, guided management substantially reduced chemotherapy intensity, especially use of the drug oxaliplatin. But the trial did not establish noninferiority. The report therefore says the cancer-related safety of de-escalation has not been established in this group.
Sam: Failing to establish noninferiority is not the same as proving the reduced treatment was worse. But it also does not give clinicians the reassurance they were seeking.
Alex: That is the distinction. The stage two result cannot simply be carried over to stage three. A negative blood test is not, by itself, a validated instruction to reduce treatment in every setting.
Sam: What about the positive patients? If the signal identifies persistent disease, did more chemotherapy improve their outcomes?
Alex: Intensification failed to improve outcomes in DYNAMIC-III. The report interprets this as a reason to pursue alternative treatment strategies, rather than just increasing the intensity of existing chemotherapy. It does not establish which alternative would work.
Sam: That makes the test useful for defining a research population, even when it does not yet provide an effective treatment choice.
Alex: Ongoing randomized studies, including CIRCULATE-US, are examining both sides. Can selected negative patients undergo surveillance instead of immediate chemotherapy? And can alternative strategies improve outcomes for patients with detectable residual disease?
Sam: What kinds of alternatives does the report describe? Are these established treatments in this setting, or candidates being tested?
Alex: They are being investigated. The approaches include immune-based treatments, cellular therapies, therapeutic vaccines, and lifestyle interventions. One randomized study compares an investigational antibody linked to a cancer drug against active surveillance in patients with persistent molecular residual disease after standard treatment.
Sam: If those studies make the blood signal disappear, that sounds encouraging. But is it enough to claim they have prevented recurrence?
Alex: No. Kopetz discusses using DNA clearance as an early endpoint to select treatments for later randomized evaluation. But clearance has not been established as a surrogate for long-term clinical benefit. In plain terms, improving that measurement does not yet prove patients live longer or avoid recurrence.
Sam: There is also a measurement problem before treatment begins. Does the test perform equally well wherever the cancer might recur?
Alex: The report says detection has generally been less reliable for lung and peritoneal metastases than for liver metastases. Peritoneal disease involves the lining of the abdominal cavity. Differences in tumor biology or DNA shedding may contribute.
Sam: So a negative result needs context. And a false positive could matter particularly when the result triggers treatment in someone with clear scans.
Alex: Kopetz stresses maintaining high assay specificity for precisely that reason: avoiding unnecessary treatment from false-positive results. He also says the biology of these tiny residual deposits remains poorly understood. They may differ from established metastatic tumors, which complicates treatment development.
Sam: Who should read the full report, and where should they start?
Alex: Researchers designing residual-disease trials and clinicians following colorectal cancer treatment should start with “ctDNA-Guided Adjuvant Chemotherapy.” Read DYNAMIC-II beside DYNAMIC-III. That comparison captures both the promise of avoiding chemotherapy and the limits of extending a successful strategy.
Sam: And for someone outside this area, deciding how much weight to give the headline?
Alex: Remember that this is a news synthesis of a presentation, not a primary trial report. Use its references for the trial details. The line to carry away is this: detecting cancer left behind and knowing how to treat it are different achievements.
Sam: Thanks for listening.